InvenireX
Invenirex is a biotechnology company focused on revolutionizing agro-industrial processes, in-vitro diagnostics, and scientific research through its proprietary Nanite Technology and R.O.S.A.L.I.N.D instrument. Their technology enables real-time, single-molecule quantification that is enzyme-free and isothermal. By leveraging machine learning, nanotechnology, and custom hardware, Invenirex aims to provide step-change advancements in detection capabilities. The company has secured a £500,000 investment and appointed Alastair Carrington as Non-Exec Chairman, indicating early-stage traction and strategic growth.
InvenireX
Invenirex is a biotechnology company focused on revolutionizing agro-industrial processes, in-vitro diagnostics, and scientific research through its proprietary Nanite Technology and R.O.S.A.L.I.N.D instrument. Their technology enables real-time, single-molecule quantification that is enzyme-free and isothermal. By leveraging machine learning, nanotechnology, and custom hardware, Invenirex aims to provide step-change advancements in detection capabilities. The company has secured a £500,000 investment and appointed Alastair Carrington as Non-Exec Chairman, indicating early-stage traction and strategic growth.
TL;DR
Founded: 2021
Founder & CEO: Dr Dan Todd
Headquarters: Newcastle upon Tyne, United Kingdom
Core tech: Enzyme-free, isothermal single-molecule DNA detection (Nanites™ + R.O.S.A.L.I.N.D™)
Stage & funding: Seed — £500,000 (Mar 2024)
Industry: Biotechnology
Company Overview
Problem Domain
Ultra-sensitive nucleic-acid detection for molecular diagnostics, life-science biosensing, in-vitro diagnostics, agro-industrial processes, and scientific research.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
£500,000
Investors reported include DSW Ventures and XTX Ventures.
Investor Signal
“Early-stage VC backing including DSW Ventures and XTX Ventures”